A woman in her late sixties steps off a curb she has stepped off a thousand times. This time her hip gives way before she reaches the ground. Surgery. A long recovery. A walker she never fully graduates from, and a quiet loss of independence that reshapes the rest of her life. Everyone around her files it under the same tidy explanation. She got older. Bones get brittle. That is just what happens.
Here is the part almost nobody catches. This did not start with the curb. It started decades earlier, when her skeleton began sending signals that no one was trained to read.
I am obsessed with muscle. Anyone who has spent five minutes with me knows that. But muscle and bone are two sides of the same coin, and I recently sat down with Dr. Doug Lucas, a fellowship-trained orthopedic surgeon who walked away from the operating room at Stanford because he was tired of cleaning up the same metabolic mess over and over again. The thing that flipped the switch for him was a 3am amputation on a young diabetic patient whose life he saved, and whose disease he knew he could have prevented. What he had to say about bone changed the way I think about it, and in my opinion it should change the way you think about it too.
Let’s get into it.
Bone Is Not the Static Scaffold You Were Taught It Was
Most of us were handed a lazy mental model of the skeleton. A dry, fixed framework that muscles happen to hang from. Something that quietly falls apart in old age and cannot be argued with.
That model is wrong, and it is costing people their independence.
Bone is a dynamic organ system. It is talking to us every day. Think about a seven year old. The growth, the open growth plates, the sheer velocity of construction happening inside that child’s body. That machinery does not shut off when you reach your peak height or your peak bone density in your late twenties. The metabolism continues. Roughly ten percent of the skeleton is remodeled each year, which means you carry enough bone metabolism to generate an entirely new skeleton approximately every decade. That is how much breakdown and rebuilding is happening under the hood, constantly.
Which means the phrase “age-related bone loss,” said with a shrug, deserves to be questioned. Devote a little suspicion to it. If bone is this active, this responsive, this alive, then losing it is not a sentence handed down by the calendar. It is a signal.
Bone Loss Is a Biomarker, Not a Verdict
The rate of bone loss depends heavily on where you are in life. Before menopause, women lose bone very slowly, around 0.13 percent per year. Starting in the fourth or fifth decade, both men and women lose bone at roughly 0.3 to 0.5 percent per year. But around menopause, that rate can accelerate dramatically, up to tenfold, meaning losses of two to two and a half percent per year, particularly in trabecular bone at the spine and hip. The simple figure of “half a percent to one percent per year” that gets tossed around blurs these very different phases together and understates the perimenopausal acceleration that matters most.
Here is the reframe that matters. In a rigorous clinical practice, patients routinely plateau that loss, and many improve their density, defying the so-called inevitable decline almost across the board, and in a way that is largely agnostic of age. Nobody outruns entropy forever. But you do not have to accept steady loss as the default for the majority of your healthspan.
So treat bone loss the way you would treat any red flag. If you are losing bone, something underneath is imbalanced. We may not know what yet, but your body is telling you to look. That is a gift, not a diagnosis to be resigned to.
The Conventional Playbook Is Reactive by Design
Here is the standard script. Wait until sixty-five, when insurance and the current screening guidance say you are statistically likely to have the disease, then order a first DEXA, then reach for a prescription. I understand the public-health math behind that timeline. I also reject it as a personal strategy, and so does Doug. At Strong Medical we get a baseline DEXA far earlier, because there is no clinical reason to wait for a problem you could have caught while it was still easy to move.
When the drugs do come, they fall into two broad camps, and understanding the difference is non-negotiable if someone hands you a prescription.
The antiresorptives, the bisphosphonates and agents like denosumab, work by slowing bone metabolism. Slow the breakdown and you also slow the buildup. In the short term that lowers fracture risk and nudges density upward, and there is a time and a place for it. But if you cannot build, you can end up with bone that is more mineralized yet potentially more fragile over the long run, and these drugs linger in the bone for a long time.
The anabolics, teriparatide and abaloparatide, actually stimulate new bone. They work beautifully alongside the levers you already control, meaning training, protein, and hormones. Most guidelines still recommend limiting treatment to about two years, though it is worth noting that the FDA has recently removed the black-box warning and formal time limitation from the teriparatide label after post-marketing data showed no increased osteosarcoma risk above background rates. Limited safety and efficacy data exist beyond two years, so the practical window remains similar, but the regulatory landscape has shifted.
The order appears to matter, and the research on sequencing is the part I find most interesting. If you suppress metabolism first with an antiresorptive and then try to build with an anabolic, the building tends to underperform. In one randomized trial, pretreatment with an oral bisphosphonate for three years attenuated the bone density response to both romosozumab and teriparatide by about one-third over twelve months. The emerging logic flips the script. Build first with the anabolic, bank as much bone as you can, then use an antiresorptive agent to defend those gains. This approach has been validated in transitions from romosozumab to denosumab, alendronate, or zoledronic acid, and from abaloparatide to alendronate, all showing further improvements or stability in spine and hip density. This is a genuinely new way of looking at it, and endocrinology is only now warming to it.
One more thing worth saying out loud. A drug that suppresses a marker is not the same as fixing the cause. If your T score moves from negative three to negative two on medication, that is meaningful, but the underlying condition can still be sitting there, the same way a normalized A1c does not erase diabetes. Suppress the number, or look for the cause. Those are two different conversations.
Quantity Is Not Quality
This is the piece that reframes everything. The real equation is not density alone. It is bone quantity plus bone quality equals fracture risk, and fracture risk is the outcome we actually care about.
DEXA measures quantity. Density. And density genuinely matters, which is why tools built on it, like the FRAX risk calculator, carry real predictive power. But a standard DEXA tells you almost nothing about quality by itself. That is a sizable gap, because you can end up denser and more brittle at the same time.
There are ways to peek at quality. CT can assess strength, though the radiation makes it a poor tool for the repeat screening we need. There is a software add-on called TBS, the trabecular bone score, that can help stratify quality using the same DEXA input, so treat it accordingly. Ultrasound-based options like REMS are making waves in the wellness space, and the data, at the moment, look inconsistent.
DEXA carries a second, less discussed limitation, and it is a big one. Scan-to-scan variability, the LSC or least significant change, can run anywhere from roughly two percent up to five percent, depending on the site and facility. Now hold that against the reality that most people’s density is only moving one to three percent per year. Inside that margin of error, you cannot always say a gain or a loss is real. Muscle, incidentally, is even slower to register change on a DEXA, which is a humbling reminder of how blunt some of our instruments are.
A quick word on the numbers you will be handed. Under fifty, ask for your Z score, which compares you to your age-matched peers. Fifty and up, the T score becomes the reference, comparing you to a healthy young adult of your sex. And here is the delicate part. Those reference populations are the general population, which means sedentary, under-fed, undertrained. So knowing where you stand is important, but do not confuse average with the goal. Aim for optimal. Ask where in that distribution you actually want to live, and then go earn it.
Your Bones Are a Window Into Your Hormones
This is where I ended up leaning in, because bone turns out to be one of the few organ systems that gives you objective, near-real-time feedback on what your hormones are doing.
Two blood markers do the heavy lifting. P1NP reflects the building side, released as your osteoblasts lay down new collagen. CTX reflects the breakdown side, released as your osteoclasts do their work. Draw them as often as you are willing to get stuck, and you can see whether you are sitting in a building-dominant or a breakdown-dominant state. These are the same markers used across the phase-three trials for bone drugs and in nutrition and supplement research. They are that useful.
Now layer hormones on top. When adequate estradiol is reaching the bone, research points to CTX dropping substantially, on the order of roughly twenty to forty percent depending on the formulation, dose, and duration of therapy. Some studies show reductions at the lower end of that range within weeks, while others approach the higher end over months. The lesson Doug and I both landed on is that a single target estradiol number is a trap. Some women suppress FSH and drop CTX on very low transdermal doses. Others sit at higher levels with CTX still stubbornly elevated, which points to a receptor story we cannot fully measure yet. It reminds me of the work on CAG repeats and androgen receptor density with testosterone, where the dose matters less than how the receptor reads it. Precision, not a one-size number.
Progesterone belongs in this conversation too. Osteoblasts carry progesterone receptors, and the natural monthly push and pull of estrogen and progesterone appears to choreograph bone building and breakdown in a rhythm. That rhythm is exactly what starts to fall out of alignment in perimenopause, especially once ovulation becomes inconsistent and progesterone drops away.
Which brings me to the timing myth I most want to bury. We talk about bone loss “at menopause,” but the graphs tell a different story. It begins during perimenopause, and the accelerated window can carry losses of roughly twelve to seventeen percent of bone density over five to seven years, with some skeletal sites like the lumbar spine potentially losing more. The opportunity to intervene is not sixty-five. It is midlife, and arguably before. Estradiol, for its part, is FDA approved for the prevention of osteoporosis, which is one of the few things in this space I can state plainly.
The Nutrition Story You Were Sold Is Mostly Wrong
Let’s talk about calcium, because it has been carrying a reputation it did not earn.
We do not live in a calcium-deficient society. Most Americans take in somewhere around seven to eight hundred milligrams a day from all sources, which is likely enough to support bone metabolism. The over-fifty recommendation of up to twelve hundred milligrams reads more like a surplus buffer. And here is the tension I could never reconcile in training. We eat a great deal of dairy and still carry some of the highest osteoporosis rates in the world. Calcium was never the whole story.
Bone is a mineral problem, not a calcium problem. If you track your intake honestly for a stretch, which I recommend, and you land under roughly eight hundred to a thousand milligrams, then add some. But do not megadose it in isolation. You need magnesium, phosphorus, and potassium alongside it. You need vitamin D, and you should be measuring your level rather than guessing. Vitamin K matters, and vitamin E, in specific forms, is emerging as a bigger player than we appreciated.
Now the myth that should have been buried and salted years ago. Protein is not bad for your bones. Protein is what bone is built from. In my geriatric fellowship, the patients with the lowest-protein diets carried the greatest fracture risk. Doug’s osteoporosis patients, when he actually tracks them, are not overeating protein. They are under-eating it, significantly. Meta-analyses consistently show that higher protein intake is associated with a meaningful reduction in hip fracture risk and possible benefits for lumbar spine density. If someone tells you to restrict protein to protect your skeleton, walk the other way.
The same goes for the alkaline diet dogma, the idea that you must “alkalize” your body to spare your bones. It does not hold. The intervention studies fail with striking consistency. An expert consensus endorsed by the European Society for Clinical and Economical Aspects of Osteoporosis and the International Osteoporosis Foundation concluded there is no evidence that diet-derived acid load is deleterious for bone health. If someone is selling you a pH protocol for your bones, that is a clean swipe left.
If I had to anchor a single food for bone the way I anchor red meat for muscle, I would land in the same place. Lean red meat. And the standout for bone specifically is the humble, unglamorous sardine. Protein, omega-3s, calcium, and minerals in one tin, bones and all. Deeply uncool on an airplane. Worth it anyway.
One caveat that underlies all of this. You can eat a rigorous diet and run a thousand-dollar supplement stack, and none of it lands if your gut cannot absorb it. Celiac disease shows up often enough that it is worth checking, and it is frequently caught precisely because someone walked in with unexplained osteoporosis. Anchor the diet, but make sure the machinery downstream is working.
The Triggers Hiding in Your Medicine Cabinet
Here is what surprises people, and plenty of physicians right along with them. Some of the most common threats to bone are sitting in the medicine cabinet.
Systemic steroids are the loud one. Oral, and even inhaled if used frequently and consistently. If that describes you, get your bone assessed. Consider this a public service announcement.
The quieter offenders are the ones people never connect. Proton pump inhibitors, the acid-reflux drugs that have drifted over the counter, are associated with increased fracture risk in multiple meta-analyses. It is worth noting that causation has not been established, and the FDA initially placed then later removed a safety warning on PPIs regarding fracture risk. The association is real, but confounding may play a role. If you are taking one for the long haul, it is worth understanding exactly why. I will tell you a story. Fifteen years ago I had a fit woman in her mid-fifties with a strange fracture, and I suggested her chronic PPI use might be interfering with mineral absorption and contributing to it. Her physical therapist called me and screamed at me for daring to say it. I still believe I was pointing at something real. Sometimes the mechanism takes years to catch up to the pattern.
SSRIs show a fairly strong association with osteoporosis as well, and I will be honest about the limits of what we know. The association is real, with meta-analyses showing a meaningfully elevated fracture risk. Serotonin receptors are present on osteoblasts, osteocytes, and osteoclasts, which provides biological plausibility. But association is not causation, and the mechanism is not clearly understood. Birth control is genuinely nuanced. Many of the synthetic progestins lean anabolic and do not appear tied to bone loss, though there are exceptions. If you are suppressing your cycle, the accountable move is simply to know what your bone is doing rather than to assume.
The takeaway mirrors everything above. Your whole medical team needs the full picture, because these decisions reach well past any single prescription.
Train Like Your Skeleton Depends On It, Because It Does
Resistance training is foundational, full stop. But bone responds to something resistance training does not fully deliver on its own, and that is impact.
Let me give you a real case. One of my patients is a sixty year old lifelong athlete, an ultra-runner who out-trains me and is three times stronger than I am. She came to us osteoporotic, which stunned me given the protein, the volume, the decades of movement. We pulled back the ultras, added structured lifting, and optimized her hormones. Over two years she has climbed from osteoporotic to osteopenic, which is real progress on a slow timeline. What she was missing, and what Doug pushed me on, is impact. No jumping, no plyometrics, no loading her skeleton with the kind of force that tells bone to build.
You do not need to leap off boxes to generate that force. There is research on something as unglamorous as the heel drop. Stand flat, rise onto the balls of your feet, then let your body weight fall with your knees essentially locked. Simple, faintly unpleasant, and capable of generating several multiples of body weight through the skeleton. Start conservatively.
On the passive end, whole-body vibration has data behind it, but the details are everything. Skip the inexpensive side-to-side plates. Skip the ultra-low-displacement devices marketed near the bone space without the evidence to back it. The versions with the best evidence use frequencies around thirty to forty hertz. Power Plate makes home units in that range. Ten minutes a day, five days a week, and you simply stand on it. There are a few contraindications, so check first, but for many people it is a genuinely low-effort lever.
I will also name the osteogenic-loading devices, the OsteoStrong and bioDensity style machines, because I know how much hope people place in them. The concept is elegant. You push against an immovable object at a joint angle where you can generate enormous force, potentially crossing the threshold that triggers bone growth. I love the idea. The randomized controlled trials that have come out recently, though, have not been convincing, and in my read they were poorly designed and largely asking the wrong question, which is who the right population even is. So the mechanism makes sense to me, and I cannot yet tell you for whom it works. Hold that one loosely.
As for the minimum effective dose, the honest answer is that we do not have a clean one, and it likely varies from person to person. Some patients in their seventies and eighties improve on two days a week of relatively light resistance. Others who are more capable need to pull the lever harder, though rarely more than three or four days of resistance, because recovery is not optional. And yes, there does appear to be a real sex difference, part biology and part the simple fact that women, on average, are not out there loading heavy and impacting their bones the way boys tend to from childhood. Men start a standard deviation or two higher and have more room to fall before they hit trouble, which is exactly why low testosterone, or aromatase inhibitor use, worries me so much in men. Blocking estrogen to chase a testosterone number makes no sense for bone, because estrogen is the primary sex-hormone driver of bone in both sexes.
Here is the through-line I keep coming back to. If you are spending enough time in a building state to add muscle, you are very likely adding bone. What is good for one is, more often than not, good for the other.
The Bottom Line
The trajectory is real. As GLP-1 medications reshape body composition on a massive scale, there is legitimate concern about accelerated bone and muscle loss in this population, though the direct effects on fracture risk are still being studied. But you are not powerless here, and I want you to sit with that.
The single most important move is the one almost nobody makes early enough. Know your starting point. Get a baseline DEXA, or a REMS if that is what you can access, but get the DEXA. Learn your T score and your Z score for your age. Understand your trajectory while you still have every lever available to change it. And if you are losing bone, do not accept a shrug. Figure out why.
A Few Things to Carry With You
Stop treating bone loss as the price of getting older. It is a biomarker. If your bone is declining, something underneath is imbalanced, and it is worth investigating rather than accepting.
Do not wait for sixty-five to look. The accelerated loss window in women opens during perimenopause, so get a baseline DEXA early and learn your Z score before fifty and your T score after.
Density is not the whole story. Fracture risk is quantity plus quality, and a standard DEXA barely sees quality, so read your results with that gap in mind.
Defend your protein. It is the raw material of bone, not a threat to it, and the alkaline-diet and calcium-only stories do not hold up. Think minerals, vitamin D, K, and E, and a protein-forward plate.
Use your bones as a hormone readout. P1NP and CTX give objective feedback that vague symptoms cannot, which makes hormone dosing far more precise.
Read past the obvious. Steroids, PPIs, SSRIs, and some hormonal contraceptives can all touch bone. Tell your whole medical team what you are taking.
Train for impact, not just load. Pair rigorous resistance work with something that loads the skeleton, and start low and go slow if your bone is already compromised.
None of this is medical advice. It is your education, so you can walk into your next appointment armed and ask better questions. If your own physician is not sure where to start, we can help through our online clinic, Strong Medical.
Until next time, stay forever strong.
